Mesenchymal stem cell alleviate concanavalin A-induced hepatitis via immune reprogramming and complement regulation - Top-Institutions - MDSpire

Mesenchymal stem cell alleviate concanavalin A-induced hepatitis via immune reprogramming and complement regulation

  • By

  • Hanpeng Luo

  • Bing Liu

  • Yaqin Li

  • Peng Cui

  • Tao Zhou

  • Cai Ye

  • Can Wu

  • Junchang Wu

  • Yu Wang

  • Wei V. Zheng

  • May 13, 2026

Share

Top Institutions in Gastroenterology

Brief introduction explaining scope and methodology.

  • #1

    Mayo Clinic
    Mayo Clinic

    Rochester, Minnesota

    Key Differentiators

    • Hepatology
    • Regenerative Medicine

  • #2

    Icahn School of Medicine at Mount Sinai
    Icahn School of Medicine at Mount Sinai

    New York, New York

    Key Differentiators

    • Hepatology
    • Liver Cancer

  • #3

    Chinese Academy of Sciences
    Chinese Academy of Sciences

    Shanghai, China

    Key Differentiators

    • Cell Biology
    • Cancer Research

  • #4

    Shanghai Cancer Institute & Department of Renji Hospital
    Shanghai Cancer Institute & Department of Renji Hospital

    Shanghai, China

    Key Differentiators

    • Cancer Research
    • Hepatology

  • #5

    Jackson Laboratory
    Jackson Laboratory

    Bar Harbor, Maine

    Key Differentiators

    • Genetics
    • Mouse Models

Original Source(s)

Mesenchymal stem cell alleviate concanavalin A-induced hepatitis via immune reprogramming and complement regulation

  • by Hanpeng Luo, Bing Liu, Yaqin Li, Peng Cui, Tao Zhou, Cai Ye, Can Wu, Junchang Wu, Yu Wang, Wei V. Zheng

  • May 13, 2026

Related Content

NPs Top US Jobs List Again

The nurse practitioner profession claims the No. 1 spot across three categories in the U.S. News & World Report 2026 Best Jobs rankings for the third consecutive year.

Curbing Drug-Related Halitosis for Closer Moments

Individuals who have drug-related halitosis may need to take additional steps to prioritize oral health before intimate encounters.

AI Scribes: Efficiency for Whom?

Unresolved safety, privacy, and regulatory concerns may limit benefits of AI scribes for physicians and patients.